Wang Y, Tortorelli C, Peyronnier A, et al 949 Inovative in vivo (in ovo) cam model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma Journal for ImmunoTherapy of Cancer 2022;10: https://dx.doi.org/10.1136/jitc-2022-SITC2022.0949
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
